JUPITER NEUROSCIENCES, INC.
JUNS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for JUNS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JUNS
Jupiter Neurosciences, Inc. is a pre-revenue biotechnology company focused on developing pharmaceutical products, currently facing significant financial challenges and a going concern uncertainty as it seeks additional capital to fund its operations and drug development programs.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$5.5M
Cash Runway
—
Lead Asset
jotrol (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for JUPITER NEUROSCIENCES, INC..
Jupiter Neurosciences, Inc. is a pre-revenue biotechnology company focused on developing pharmaceutical products, currently facing significant financial challenges and a going concern uncertainty as it seeks additional capital to fund its operations and drug development programs.
- Jupiter Neurosciences reported $0.0M in total revenue and a net loss of -$2.3M for the period ended 2026-06-30 [sec].
- The company's shareholders' equity was -$1.8M as of 2026-06-30 [sec].
- The company's audit report for fiscal years 2025 and 2024 includes a going concern qualification [sec · filed 2026-06-26].
- As of September 30, 2025, the company had $723,797 in cash [sec · filed 2025-11-26].
- The company anticipates needing substantial additional capital to finance operations and drug development, with failure to raise capital potentially forcing delays or elimination of programs [sec · filed 2026-06-26].
What works
- The company is developing product candidates such as JOTROL™, which may address unmet medical needs if successfully developed and approved [sec · filed 2025-11-26].
- The company has identified multiple factors that could influence its capital needs, indicating a structured approach to planning its development pipeline [sec_mda · as of 2026-05-14].
What to weigh
- The company has a going concern qualification in its audit reports for fiscal years 2025 and 2024, indicating substantial doubt about its ability to continue as a going concern [sec · filed 2026-06-26].
- The company has no revenue and a history of recurring losses and negative cash flows from operations [sec_mda · as of 2026-05-14].
- The company's cash position of $723,797 as of September 30, 2025, is very limited relative to the substantial capital required for drug development [sec · filed 2025-11-26].
- Raising additional capital may cause substantial dilution to stockholders or require the company to relinquish rights to its technologies or product candidates [sec · filed 2026-06-26].
From the filings
Quoted directly from source documents.
The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
“continue as a going concern in its audit report for the fiscal years ended December 31, 2025 and 2024;”
SEC filings · June 26, 2026
The company requires substantial additional capital to finance operations and may be forced to delay or eliminate programs if unable to raise it.
“We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts;”
SEC filings · June 26, 2026
The company had $723,797 in cash as of September 30, 2025.
“As of September 30, 2025, we had $723,797 in cash.”
SEC filings · November 26, 2025
The company has a history of recurring losses and negative cash flows from operations.
“our historical recurring losses and negative cash flows from operations as well as our dependence on private equity and financings.”
SEC MD&A · May 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Auditors have expressed substantial doubt about the company's ability to continue as a going concern [sec · filed 2026-06-26].
- Insufficient cash runway — Cash of $723,797 as of Sep 30, 2025, is very limited for drug development costs [sec · filed 2025-11-26].
- Dependence on external financing — Failure to raise capital could force delay or elimination of development programs [sec · filed 2026-06-26].
- Potential stockholder dilution — Raising additional capital may cause substantial dilution to stockholders [sec · filed 2026-06-26].
What to watch
- Ability to raise additional capital on acceptable terms, as failure could force program delays or elimination [sec · filed 2026-06-26].
- Progress of preclinical studies and clinical trials for product candidates like JOTROL™ [sec · filed 2025-11-26].
- Changes in cash position and operating expenses in future financial filings [sec_mda · as of 2026-05-14].
- Any updates on the company's ability to resolve the going concern qualification [sec · filed 2026-06-26].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run JUPITER NEUROSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available JUPITER NEUROSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF -$2M · Net income -$2M
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 21, 2026- % of float
- 0.6%
- Days to cover
- 0.7
- Shares short
- 126,917
- Daily short volume (May 8, 2026)
- 28.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
JUNS short interestGovernance
Frequently asked questions
What is the AI investment thesis for JUPITER NEUROSCIENCES, INC.?
Jupiter Neurosciences, Inc. is a pre-revenue biotechnology company focused on developing pharmaceutical products, currently facing significant financial challenges and a going concern uncertainty as it seeks additional capital to fund its operations and drug development programs.
What is JUPITER NEUROSCIENCES, INC.'s lead drug candidate?
JUPITER NEUROSCIENCES, INC.'s most advanced tracked candidate is jotrol (Phase 2) for Friedreich's ataxia.
Who is the CEO of JUPITER NEUROSCIENCES, INC.?
Mr. Christer Rosen is the chief executive officer of JUPITER NEUROSCIENCES, INC. (JUNS).
Where is JUPITER NEUROSCIENCES, INC. headquartered?
JUPITER NEUROSCIENCES, INC. (JUNS) is headquartered in Jupiter, FL, United States.
What therapeutic areas does JUPITER NEUROSCIENCES, INC. focus on?
JUPITER NEUROSCIENCES, INC. develops therapies across Rare Disease, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.